Precision Medicine will need to get out of the pharma silo that is based on symptoms

Welcome to the digital era of biology (and to this modest blog I started in early 2005).

To cure many diseases, like cancer or cystic fibrosis, we will need to target genes (mutations, for ex.), not organs! I am convinced that the future of replacement medicine (organ transplant) is genomics (the science of the human genome). In 10 years we will be replacing (modifying) genes; not organs!

Anticipating the $100 genome era and the P4™ medicine revolution. P4 Medicine (Predictive, Personalized, Preventive, & Participatory): Catalyzing a Revolution from Reactive to Proactive Medicine.

After low-cost airlines (Ryanair, Easyjet ...) comes "low-cost" participatory medicine. Some of my readers have recently christened this long-lasting, clumsy attempt at e-writing of mine "THE LOW-COSTE INNOVATION BLOG". I am an
early adopter of scientific MOOCs. My name's Catherine Coste. I've earned myself four MIT digital diplomas: 7.00x, 7.28x1, 7.28.x2 and 7QBWx. Instructor of 7.00x: Eric Lander PhD.

Upcoming books: Airpocalypse, a medical thriller (action taking place in Beijing) 2017; Jesus CRISPR Superstar, a sci-fi -- French title: La Passion du CRISPR (2018).

I love Genomics. Would you rather donate your data, or... your vital organs?

Audio files on this blog are Windows files ; if you have a Mac, you might want to use VLC ( to read them.

Concernant les fichiers son ou audio (audio files) sur ce blog : ce sont des fichiers Windows ; pour les lire sur Mac, il faut les ouvrir avec VLC (

23andMe Wants to Take Its DNA Tests Mass-Market

"On Sept. 30, it will launch a massive open online course on human genetics titled 'Tales from the Genome,' with Udacity.
More important, perhaps, 23andMe is about to announce a private-sector partnership that could be a model for bringing millions more consumers on board. 'The most important thing right now is scale,' says Page. 'Once we get that, then the business model will follow.' Opportunities could range from new areas of research to services aimed at communities that form around particular traits or ancestry.
23andMe, named after the 23 pairs of chromosomes that each person carries, has some natural advantages in the race to establish the leading direct-to-consumer genomics firm. The firm pioneered the use of crowdsourced genetic data for research on diseases such as Parkinson’s, myeloproliferative neoplasms, and sarcoma. Another is the high profile of its chief executive officer and co-founder, Anne Wojcicki. A biologist turned businesswoman, Wojcicki recently separated from her husband, Google (GOOG) co-founder Sergey Brin, who’s invested millions in the company."

Aucun commentaire: